Asia Pacific Digital Diabetes Management Market size surpassed USD 2.5 billion in 2020 and is anticipated to expand at a CAGR of 19.5% from 2021 to 2027.
Digital diabetes management solutions include both devices and services. The digital diabetes management solutions include devices that can be connected through smart phone to management software and apps. This includes both insulin delivery and monitoring devices that can connect with smart phones or apps.
Get more details on this report - Request Free Sample PDF
Continuous technological advancement and increasing number of product launches are the factors contributing to the APAC digital diabetes management industry growth. New technologies in digital diabetes space are allowing individualization of care, as patients can work with their healthcare providers to determine which digital device is best fit for their lifestyle and need. Furthermore, continuous improvement in glucose monitoring technologies is also allowing patients to simultaneously reduce hypoglycaemia and improve glycaemic control.
Increasing burden of diabetes in the region coupled with increasing awareness about diabetes preventive care are the factors contributing to the market growth. In addition, launch of several government initiatives to curb the diabetes burden is also contributing to the market growth. For instance, in November 2019, the Indian Medical Association (IMA) launched the screening camps and mass awareness programmes to spread awareness about the disease. The campaign includes series of events such as interactive seminars, diabetes screening camps, and mass awareness programs.
APAC Market, By Product Type
Smart CGM segment revenue was over USD 950 million in 2020 owing to continuous technological advancements and increasing adoption rate of continuous glucose monitors. CGM devices have become increasingly reliable and have great efficacy in reducing hypoglycemia and time in delivering target glucose range. Incremental progress in CGM technology is moving towards fully functional artificial pancreas. As more data is presented to healthcare providers and patients, immediate feedback to patients is providing better outcome, creating demand for the market.
APAC Market, By Patient Type
Type 2 diabetes patient segment is predicted to register a growth of over 19.5% through 2027 due to presence of large type 2 patients in the region. The type 2 diabetes is the most common form of diabetes and it affects 80-90% of all people living with diabetes.
APAC Market, By End-use
Homecare settings segment will observe a growth of more than 19.8% till 2027. Increasing awareness about diabetes preventive care coupled with user friendly interface of digital diabetes devices are increasing the demand for homecare devices. Moreover, presence of large geriatric population is also increasing the usage of digital diabetes devices in home settings.
APAC Market, By Country
China digital diabetes management market held over 19% revenue share in 2020. According to the International Diabetes Federation, more than 116 million people were living with diabetes in 2019 in China. China held the largest diabetes population in the world with the prevalence rate of 10.9% and majority of it depends heavily upon insulin. Furthermore, with the economic development of country, the cost of diabetes per person has also increased from USD 115.0 in 2010 to USD 936.2 in 2019. Thus, with presence of more than 54 million people with impaired glucose tolerance, the country is expected to maintain its dominant position in Asia Pacific during the forecast period.
Competitive Market Share
Few of the established major industry players include Abbott Laboratories, Medtronic Plc, Insulet Corporation, F. Hoffmann-LA Roche Ltd., Dexcom, Inc., Companion Medical, Ypsomed, Tandem Diabetes, and Glooko, Inc., among several others. These players are continuous innovating their product and are involved in technological collaborations to cater to growing patient pool. For instance, in November 2020, Microsoft in China and Novo Nordisk A/s announced the collaboration to develop Chinese-speaking AI chatbot for diabetes patients. The collaboration will improve diabetes knowledge of Chinese people.